Acute myocardial infarction
Conditions
Interventions
10×10^5 cells/kg SVF was injected intravenously:10×10^5 cells/kg SVF was injected intravenously at 24h and one month after surgery
20×10^5cells/kg SVF was injected intravenously:20×10^5 cells/kg SVF was injected intravenously at 24h and one month after surgery
Intravenous saline at the same dose:The same dose of normal saline was injected intravenously 24h and one month after surgery
Sponsors
The Second Affiliated Hospital of Air Force Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. 18 years old 30 minutes, V2, V3 0.2 mV) or new-onset left bundle branch resistance (LBBB 3), cardiac biomarker (troponin, CK-MB) elevation beyond the 99th percentile of the upper limit of the laboratory reference at the time of admission; 4. The lesion of the offender is an orthotopic lesion, which is limited to a single lesion in the proximal and mid-segment of the anterior descending artery. 5. Sign the written informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those who know or are expected to have allergic reactions or history of allergies to any of the ingredients treated in this test; 2. The investigator judges that the patient is not suitable to participate in this study for other reasons; 3. Hemodynamic instability; 4. Thrombolysis with intravenous drugs; 5. Those who cannot pass through the thrombus aspiration catheter or the coronary artery diameter is narrowed by =70% after thrombus aspiration; 6. Left main lesion; 7. AMI is caused by surgery, trauma, gastrointestinal bleeding or PCI or is a complication thereof; 8. AMI occurs in patients who have been hospitalized for other reasons; 9. The investigator judged that the patient's compliance was poor and he was unable to complete the study as required; 10. Life expectancy <=12 months; 11. Heart transplant patients; 12. Patients with a clear diagnosis of tumors; 13. Patients who are participating in other clinical trials (except for other topics of this project) and have not reached the time limit of the main study endpoint.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The echocardiographic examination index of the patient 30 days after surgery;Whether there is any allergic reaction to the local injection part;Whether the patient has an allergic reaction to the SVF component;Incidence and severity of AE;Incidence and severity of SAE; | — |
Secondary
| Measure | Time frame |
|---|---|
| Major cardiovascular adverse events;Echocardiographic examination indicators;Myocardial infarction size;Myoglobin (MB), cardiac troponin I (cTnI), cardiac troponin T (cTnT);Myocardial zymogram; | — |
Countries
China
Contacts
Public ContactLi yan
The Second Affiliated Hospital of Air Force MedicalUniversity
Outcome results
None listed